A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule

被引:153
|
作者
Fagart, Jerome [6 ]
Hillisch, Alexander [2 ]
Huyet, Jessica [6 ]
Baerfacker, Lars [2 ]
Fay, Michel [6 ]
Pleiss, Ulrich [3 ]
Pook, Elisabeth [4 ]
Schaefer, Stefan [1 ]
Rafestin-Oblin, Marie-Edith [5 ,6 ]
Kolkhof, Peter [1 ]
机构
[1] Bayer Schering Pharma AG, Dept Cardiol Res, Global Drug Discovery, D-42096 Wuppertal, Germany
[2] Bayer Schering Pharma AG, Dept Med Chem, Global Drug Discovery, D-42096 Wuppertal, Germany
[3] Bayer Schering Pharma AG, Dept Isotope Chem, Global Drug Discovery, D-42096 Wuppertal, Germany
[4] Bayer Schering Pharma AG, Dept Lead Discovery, Global Drug Discovery, D-42096 Wuppertal, Germany
[5] CRB3, INSERM, U773, F-75870 Paris, France
[6] Univ Paris 07, F-75018 Paris, France
关键词
CALCIUM-CHANNEL BLOCKERS; LIGAND-BINDING DOMAIN; STRUCTURAL BASIS; ALDOSTERONE BLOCKER; ANDROGEN RECEPTOR; HEART-FAILURE; HYPERTENSION; MECHANISMS; PSEUDOHYPOALDOSTERONISM; MUTATIONS;
D O I
10.1074/jbc.M110.131342
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Limitations of current steroidal mineralocorticoid receptor (MR) antagonists have stimulated the search for a new generation of molecules. We screened for novel nonsteroidal compounds and identified MR antagonists derived from the chemical class of dihydropyridines. Chemical optimization resulted in BR-4628, which displays high in vitro and in vivo MR potency as well as selectivity with respect to the other steroid hormone receptors and the L-type calcium channel. Biochemical studies demonstrated that BR-4628 forms complexes with MR that do not promote the recruitment of transcriptional co-regulators. Docking experiments, using the crystal structure of the MR ligand-binding domain in an agonist conformation, revealed that BR-4628 accommodates in the MR ligand-binding cavity differently in comparison with the classical steroidal MR antagonists. An alanine scanning mutagenesis approach, based on BR-4628 docking, allowed identifying its anchoring mode within the ligand-binding cavity. Altogether, we propose that BR-4628 is a bulky antagonist that inactivates MR through a passive mechanism. It represents the prototype of a new class of MR antagonists.
引用
收藏
页码:29932 / 29940
页数:9
相关论文
共 50 条
  • [1] Is there a new dawn for selective mineralocorticoid receptor antagonism?
    Luther, James M.
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2014, 23 (05): : 456 - 461
  • [2] Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
    Sueta, Daisuke
    Yamamoto, Eiichiro
    Tsujita, Kenichi
    [J]. CURRENT HYPERTENSION REPORTS, 2020, 22 (03)
  • [3] Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
    Daisuke Sueta
    Eiichiro Yamamoto
    Kenichi Tsujita
    [J]. Current Hypertension Reports, 2020, 22
  • [4] Perspective on Nonsteroidal Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease
    Ghuman, Jasleen K.
    Tuttle, Katherine R.
    [J]. KIDNEY360, 2022, 3 (04): : 744 - 748
  • [5] Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy
    Kolkhof, Peter
    Joseph, Amer
    Kintscher, Ulrich
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 172
  • [6] Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist
    Iijima, Toru
    Katoh, Makoto
    Takedomi, Kei
    Yamamoto, Yasuo
    Akatsuka, Hidenori
    Shirata, Naritoshi
    Nishi, Akito
    Takakuwa, Misae
    Watanabe, Yoshinori
    Munakata, Hitomi
    Koyama, Naomi
    Ikeda, Tomoko
    Iguchi, Taku
    Kato, Harutoshi
    Kikkawa, Kohei
    Kawaguchi, Takayuki
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (12) : 8127 - 8143
  • [7] Identification of Benzoxazin-3-one Derivatives as Novel, Potent, and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
    Hasui, Tomoaki
    Matsunaga, Nobuyuki
    Ora, Taiichi
    Ohyabu, Norio
    Nishigaki, Nobuhiro
    Imura, Yoshimi
    Igata, Yumiko
    Matsui, Hideki
    Motoyaji, Takashi
    Tanaka, Toshimasa
    Habuka, Noriyuki
    Sogabe, Satoshi
    Ono, Midori
    Siedem, Christopher S.
    Tang, Tony P.
    Gauthier, Cassandra
    De Meese, Lisa A.
    Boyd, Steven A.
    Fukumoto, Shoji
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (24) : 8616 - 8631
  • [8] Mineralocorticoid Receptor Antagonism in AKI: A New Hope?
    Juncos, Luis A.
    Juncos, Luis I.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (02): : 335 - 337
  • [9] Nonsteroidal antagonists of the mineralocorticoid receptor
    Kolkhof, Peter
    Nowack, Christina
    Eitner, Frank
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2015, 24 (05): : 417 - 424
  • [10] Discovery of Benzimidazole Oxazolidinediones as Novel and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
    Yang, Christine
    Balsells, Jaume
    Chu, Hong D.
    Cox, Jason M.
    Crespo, Alejandro
    Ma, Xiuying
    Contino, Lisa
    Brown, Patricia
    Gao, Sheng
    Zamlynny, Beata
    Wiltsie, Judyann
    Clemas, Joseph
    Lisnock, Jean Marie
    Gibson, Jack
    Zhou, Gaochao
    Garcia-Calvo, Margarita
    Bateman, Thomas J.
    Tong, Vincent
    Xu, Ling
    Crook, Martin
    Sinclair, Peter
    Shen, Hong C.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (04): : 461 - 465